Abstract Search

ea0029p788 | Endocrine tumours and neoplasia | ICEECE2012

Is combined radionuclide therapy with 90y-Dotatate and 177lu-Dotatate an effective treatment option for patients with metastasised neuroendocrine tumours? An ongoing study

Seregni E. , Vincenzo M. , Braud De F. , Buzzoni R. , Marco M. , Coliva A. , Pascali C. , Mallia A. , Bombardieri E.

Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of β-emitting radioisotopes has been reported.Aim: Ongoing study to evaluate efficacy and toxicity of combination treatment with 4 cycles of radiolabeled DOTATATE, alternating 177Lu and 90Yin patients with metastasised NETs expressing SRs refract...

0 shares

Endocrine Abstracts

Is combined radionuclide therapy with 90y-Dotatate and 177lu-Dotatate an effective treatment option for patients with metastasised neuroendocrine tumours? An ongoing study

BiosciAbstracts